

BRACAnalysis CDx plus Lynparza gets approval

written by CAP TODAY

February 19, 2020

February 2020—Myriad Genetics announced that the FDA has approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor olaparib (Lynparza, AstraZeneca). BRACAnalysis CDx is the first FDA-approved genetic test for this indication, the company reports.

[Myriad Genetics](#), 801-584-3600



©2026 CAP TODAY, all rights reserved.